1. Home
  2. MESO

as 07-12-2024 4:00pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

Mesoblast Ltd is a clinical-stage biotechnology company. It develops and commercializes innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care. Its portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), and for moderate to severe acute respiratory distress syndrome (ARDS) and others.

Founded: 2004 Country:
Australia
Australia
Employees: N/A City: N/A
Market Cap: 820.6M IPO Year: N/A
Target Price: $7.00 AVG Volume (30 days): 141.6K
Analyst Decision: Hold Number of Analysts: 6
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.91 EPS Growth: N/A
52 Week Low/High: $1.61 - $10.24 Next Earning Date: 08-28-2024
Revenue: $7,253,000 Revenue Growth: -10.69%
Revenue Growth (this year): -13.76% Revenue Growth (next year): 71.31%

MESO Daily Stock ML Predictions

Share on Social Networks: